Min H. Kang

发表

Bcl-2 Inhibitors: Targeting Mitochondrial Apoptotic Pathways in Cancer Therapy

C. Reynolds, Min H. Kang, P. Reynolds, 2009, Clinical Cancer Research.

Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed/refractory neuroblastoma: A report from the new approaches to neuroblastoma therapy (NANT) consortium

S. Groshen, J. Maris, K. Matthay, 2013, Pediatric blood & cancer.

Initial testing of the investigational NEDD8‐activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2012, Pediatric blood & cancer.

Initial testing (stage 1) of the multi‐targeted kinase inhibitor sorafenib by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2010, Pediatric blood & cancer.

Initial testing (stage 1) of AZD6244 (ARRY‐142886) by the pediatric preclinical testing program

Peter J Houghton, John M Maris, Richard Gorlick, 2010, Pediatric blood & cancer.

Initial solid tumor testing (Stage 1) of AZD1480, an inhibitor of Janus kinases 1 and 2 by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2014, Pediatric blood & cancer.

Reversal of multidrug resistance: lessons from clinical oncology.

T. Fojo, R. Robey, Clara C. Chen, 2002, Novartis Foundation symposium.

Tumor-Associated Macrophages as Multifaceted Regulators of Breast Tumor Growth

N. Moustaid‐Moussa, S. Rahman, A. Al-Harrasi, 2021, International journal of molecular sciences.

in human acute lymphoblastic leukemia cell lines Caspase-dependent Mcl-1 cleavage and effect of Mcl-1 phosphorylation in ABT-737-induced apoptosis

C. Reynolds, Min H. Kang, Connor P Hall, 2014 .

Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models

K. Cole, J. Maris, B. Teicher, 2018, Clinical Cancer Research.

Initial testing (stage 1) of the IGF‐1 receptor inhibitor BMS‐754807 by the pediatric preclinical testing program

Richard Gorlick, S. Keir, J. Maris, 2011, Pediatric blood & cancer.

558 POSTER Pediatric Preclinical Testing Program (PPTP) evaluation of the fully human anti-IGF-1R antibody IMC-A12

J. Maris, P. Houghton, H. Friedman, 2008 .

Initial testing of a monoclonal antibody (IMC‐A12) against IGF‐1R by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2010, Pediatric blood & cancer.

Fenretinide metabolism in humans and mice: utilizing pharmacological modulation of its metabolic pathway to increase systemic exposure

Simon C. Williams, C. Reynolds, Min H. Kang, 2011, British journal of pharmacology.

Gibberellin derivative GA-13315 sensitizes multidrug-resistant cancer cells by antagonizing ABCB1 while agonizes ABCC1

Min H. Kang, Hong-Bin Zhang, Jingbo Chen, 2016, Cancer Chemotherapy and Pharmacology.

Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial

S. Groshen, K. Matthay, D. Haas-Kogan, 2018, Pediatric blood & cancer.

Aggravation of L-DOPA-induced neurotoxicity by tetrahydropapaveroline in PC12 cells.

Jae Joon Lee, J. Hong, Myung-Koo Lee, 2003, Biochemical pharmacology.

Initial testing (stage 1) of the polo‐like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program

S. Keir, J. Maris, P. Houghton, 2014, Pediatric blood & cancer.

Initial testing (stage 1) of the anti‐microtubule agents cabazitaxel and docetaxel, by the Pediatric Preclinical Testing Program

J. Maris, P. Houghton, Malcolm A. Smith, 2015, Pediatric blood & cancer.

Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2015, Pediatric blood & cancer.

Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2013, Pediatric blood & cancer.

Antineoplastic Agents Targeting Sphingolipid Pathways

Alexander Kroll, Min H. Kang, H. Cho, 2020, Frontiers in Oncology.

Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2012, Pediatric blood & cancer.

C22:0- and C24:0-dihydroceramides Confer Mixed Cytotoxicity in T-Cell Acute Lymphoblastic Leukemia Cell Lines

Min H. Kang, B. Maurer, S. Cox, 2013, PloS one.

Metabolic characteristics of 13‐cis‐retinoic acid (isotretinoin) and anti‐tumour activity of the 13‐cis‐retinoic acid metabolite 4‐oxo‐13‐cis‐retinoic acid in neuroblastoma

C. Reynolds, Min H. Kang, A. Yu, 2014, British journal of pharmacology.

Cytotoxicity and molecular activity of fenretinide and metabolites in T-cell lymphoid malignancy, neuroblastoma, and ovarian cancer cell lines in physiological hypoxia

C. Reynolds, Min H. Kang, B. Maurer, 2019, Anti-cancer drugs.

Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT‐330): A report from the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2016, Pediatric blood & cancer.

A phase I study of intravenous fenretinide (4-HPR) for patients with malignant solid tumors

S. Groshen, J. Pinski, D. Gandara, 2021, Cancer Chemotherapy and Pharmacology.

Phase I Study of Fenretinide Delivered Intravenously in Patients with Relapsed or Refractory Hematologic Malignancies: A California Cancer Consortium Trial

S. Groshen, A. Yang, S. Kummar, 2017, Clinical Cancer Research.

Initial testing (Stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2012, Pediatric blood & cancer.

Initial testing of topotecan by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2010, Pediatric blood & cancer.

c-Abl Is an Upstream Regulator of Acid Sphingomyelinase in Apoptosis Induced by Inhibition of Integrins αvβ3 and αvβ5

A. Erdreich-Epstein, Jingying Xu, Min H. Kang, 2012, PloS one.

A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High‐Risk Neuroblastoma

S. Groshen, J. Maris, K. Matthay, 2016, Pediatric blood & cancer.

Initial testing of JNJ‐26854165 (Serdemetan) by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2012, Pediatric blood & cancer.

Development of cell‐based high throughput luminescence assay for drug discovery in inhibiting OCT4/DNA‐PKcs and OCT4–MK2 interactions

K. Dalby, Shengping Yang, Sung-Jen Wei, 2021, Biotechnology and bioengineering.

Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2014, Pediatric blood & cancer.

Retrospective Evaluation of Heptaplatin Toxicities in Patients with Advanced Gastric Cancer

Myung-Koo Lee, Min H. Kang, S. Lim, 2006 .

Methotrexate and aminopterin exhibit similar in vitro and in vivo preclinical activity against acute lymphoblastic leukaemia and lymphoma

R. Lock, Min H. Kang, Connor P Hall, 2009, British journal of haematology.

Initial testing of VS‐4718, a novel inhibitor of focal adhesion kinase (FAK), against pediatric tumor models by the Pediatric Preclinical Testing Program

S. Keir, J. Maris, P. Houghton, 2017, Pediatric blood & cancer.

Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2013, Pediatric blood & cancer.

Initial testing (stage 1) of the phosphatidylinositol 3′ kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2013, Pediatric blood & cancer.

Effects of (1R,9S)-β-hydrastine on l-DOPA-induced cytotoxicity in PC12 cells

Myung-Koo Lee, Jae-Joon Lee, Min H. Kang, 2004 .

Fenretinide cytotoxicity is independent of both constitutive and pharmacologically modulated glutathione levels in pediatric acute lymphoblastic leukemia cells cultured at hypoxia

Min H. Kang, J. Cooper, Hardeep Singh, 2012, Pediatric blood & cancer.

P450 inhibitor ketoconazole increased the intratumor drug levels and antitumor activity of fenretinide in human neuroblastoma xenograft models

C. Reynolds, Min H. Kang, B. Maurer, 2017, International journal of cancer.

Reactive Oxygen Species–Mediated Synergism of Fenretinide and Romidepsin in Preclinical Models of T-cell Lymphoid Malignancies

C. Reynolds, Min H. Kang, M. R. Makena, 2017, Molecular Cancer Therapeutics.

Vorinostat and fenretinide synergize in preclinical models of T-cell lymphoid malignancies

C. Reynolds, Min H. Kang, C. Reynolds, 2020, Anti-cancer drugs.

Initial testing of lenalidomide by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2011, Pediatric blood & cancer.

Initial testing (Stage 1) of the antibody‐maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2013, Pediatric blood & cancer.

B- to plasma-cell terminal differentiation entails oxidative stress and profound reshaping of the antioxidant responses.

J. Fujii, S. Rhee, S. Masciarelli, 2010, Antioxidants & redox signaling.

Inhibitory effects of tributyltin on dopamine biosynthesis in rat PC12 cells

Jae Joon Lee, Myung-Koo Lee, Min H. Kang, 2002, Neuroscience Letters.

Initial testing (stage 1) of LCL161, a SMAC mimetic, by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2012, Pediatric blood & cancer.

Enantio-selective inhibition of (1R,9S)- and (1S,9R)-β-hydrastines on dopamine biosynthesis in PC12 cells

Jae Joon Lee, Myung-Koo Lee, Min H. Kang, 2004, Neuropharmacology.

Ceramide synthase-6 confers resistance to chemotherapy by binding to CD95/Fas in T-cell acute lymphoblastic leukemia

Shengping Yang, Sung-Jen Wei, Min H. Kang, 2018, Cell Death & Disease.

Initial testing of the aurora kinase a inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP)

Peter J Houghton, John M Maris, Richard Gorlick, 2010, Pediatric blood & cancer.

Testing of the Akt/PKB inhibitor MK‐2206 by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2012, Pediatric blood & cancer.

Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer

S. Keir, J. Maris, P. Houghton, 2011, Cancer Chemotherapy and Pharmacology.

Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ‐26481585), by the Pediatric Preclinical Testing Program

S. Keir, J. Maris, P. Houghton, 2014, Pediatric blood & cancer.

National Cancer Institute pediatric preclinical testing program: Model description for in vitro cytotoxicity testing

P. Houghton, C. Morton, Malcolm A. Smith, 2011, Pediatric blood & cancer.

MYC transcription activation mediated by OCT4 as a mechanism of resistance to 13-cisRA-mediated differentiation in neuroblastoma

H. Shimada, Shengping Yang, Sung-Jen Wei, 2020, Cell Death & Disease.

Fenretinide via NOXA Induction, Enhanced Activity of the BCL-2 Inhibitor Venetoclax in High BCL-2–Expressing Neuroblastoma Preclinical Models

Sung-Jen Wei, C. Reynolds, Min H. Kang, 2019, Molecular Cancer Therapeutics.

Cytotoxic activity of difluoromethylornithine compared with fenretinide in neuroblastoma cell lines

C. Reynolds, Min H. Kang, C. Reynolds, 2018, Pediatric blood & cancer.

Evaluation of Alternative In Vivo Drug Screening Methodology: A Single Mouse Analysis.

Peter J Houghton, John M Maris, Richard Gorlick, 2016, Cancer research.

Role of OCT4 in cancer stem-like cells and chemotherapy resistance.

Sung-Jen Wei, Min H. Kang, Ismail S. Mohiuddin, 2020, Biochimica et biophysica acta. Molecular basis of disease.

DNA-PK as an Emerging Therapeutic Target in Cancer

Min H. Kang, Ismail S. Mohiuddin, 2019, Front. Oncol..

Initial Testing (Stage 1) of MK‐8242—A Novel MDM2 Inhibitor—by the Pediatric Preclinical Testing Program

S. Keir, J. Maris, P. Houghton, 2016, Pediatric blood & cancer.

Pharmacokinetic Modeling of an Induction Regimen for In Vivo Combined Testing of Novel Drugs against Pediatric Acute Lymphoblastic Leukemia Xenografts

R. Lock, C. Stewart, C. Reynolds, 2012, PloS one.

HPLC analysis and pharmacokinetic characteristics of 11-hydroxyaclacinomycin X (ID-6105), a novel anthracycline, in rats and beagle dogs.

Sukgil Song, Y. Chung, Min H. Kang, 2005, Biological & pharmaceutical bulletin.

Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2010, Pediatric blood & cancer.

Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.

S. Bates, A. Fojo, S. Balcerzak, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Initial testing of the MDM2 inhibitor RG7112 by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2013, Pediatric blood & cancer.

Mithramycin induces promoter reprogramming and differentiation of rhabdoid tumor

Gabrielle E Foxa, B. Williams, P. Grohar, 2020, EMBO molecular medicine.

Preservation of high glycolytic phenotype by establishing new acute lymphoblastic leukemia cell lines at physiologic oxygen concentration.

Matthew V. Ghent, S. Asgharzadeh, Lingyun Ji, 2015, Experimental Cell Research.

A Phase I/II Study of Infusional Vinblastine with the P-Glycoprotein Antagonist Valspodar (PSC 833) in Renal Cell Carcinoma

S. Steinberg, P. Choyke, T. Fojo, 2004, Clinical Cancer Research.

Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program

S. Keir, J. Maris, P. Houghton, 2014, Clinical Cancer Research.

Bcl-2 family of proteins as therapeutic targets in genitourinary neoplasms.

W. Figg, D. Price, Min H. Kang, 2013, Clinical genitourinary cancer.

A phase I trial of depsipeptide (FR901228) in patients with advanced cancer.

J. Marshall, N. Rizvi, W. Figg, 2002, Journal of experimental therapeutics & oncology.

Testing of the topoisomerase 1 inhibitor Genz‐644282 by the pediatric preclinical testing program

S. Keir, J. Maris, B. Teicher, 2012, Pediatric blood & cancer.

Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2017, Pediatric blood & cancer.

Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673

S. Keir, J. Maris, O. Hampton, 2015, Pediatric blood & cancer.

Identi fi cation of Mithramycin Analogues with Improved Targeting of the EWS-FLI 1 Transcription Factor

L. Turner, S. Lessnick, L. Helman, 2016 .

Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ‐secretase inhibitor targeting notch signaling

S. Keir, J. Maris, P. Houghton, 2012, Pediatric blood & cancer.

Activity of MM-398, Nanoliposomal Irinotecan (nal-IRI), in Ewing's Family Tumor Xenografts Is Associated with High Exposure of Tumor to Drug and High SLFN11 Expression

T. Triche, J. Fitzgerald, D. Drummond, 2015, Clinical Cancer Research.

Initial testing of the CENP‐E inhibitor GSK923295A by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2012, Pediatric blood & cancer.

Initial testing (stage 1) of the polyamine analog PG11047 by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2011, Pediatric blood & cancer.

Initial testing of the replication competent Seneca Valley virus (NTX‐010) by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2010, Pediatric blood & cancer.

Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235

C. Reynolds, Min H. Kang, Connor P Hall, 2015, Clinical Cancer Research.

pH gradient-liquid chromatography tandem mass spectrometric assay for determination of underivatized polyamines in cancer cells.

Min H. Kang, H. Cho, 2018, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Evaluation of cytarabine against Ewing sarcoma xenografts by the pediatric preclinical testing program

P. Houghton, C. Morton, Malcolm A. Smith, 2010, Pediatric blood & cancer.

Initial testing (stage 1) of the notch inhibitor PF‐03084014, by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2014, Pediatric blood & cancer.

Preclinical Activity of MM-398 , Nanoliposomal Irinotecan ( nal-IRI ) , in Ewing ' s Family Tumor Xenografts Is Associated with High Exposure of Tumor to Drug and High SLFN 11 Expression

T. Triche, J. Fitzgerald, D. Drummond, 2015 .

Caspase-dependent Mcl-1 cleavage and effect of Mcl-1 phosphorylation in ABT-737-induced apoptosis in human acute lymphoblastic leukemia cell lines

C. Reynolds, Min H. Kang, Connor P Hall, 2014, Experimental biology and medicine.

Hydrophilic interaction liquid chromatography-tandem mass spectrometric approach for simultaneous determination of safingol and D-erythro-sphinganine in human plasma.

C. Reynolds, Min H. Kang, B. Maurer, 2019, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Stage 2 Combination Testing of Rapamycin with Cytotoxic Agents by the Pediatric Preclinical Testing Program

S. Keir, L. Rubinstein, J. Maris, 2010, Molecular Cancer Therapeutics.

Initial testing (stage 1) of SGI‐1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2012, Pediatric blood & cancer.

Retrospective Evaluation for Efficacy and Tolerance of beta-blocker in Heart FailurePatients with Concomitant Diabetes

Myung-Koo Lee, Min H. Kang, S. Lim, 2006 .

Initial testing (stage 1) of M6620 (formerly VX‐970), a novel ATR inhibitor, alone and combined with cisplatin and melphalan, by the Pediatric Preclinical Testing Program

P. Houghton, Malcolm A. Smith, Min H. Kang, 2018, Pediatric blood & cancer.

Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program

Peter J Houghton, John M Maris, Richard Gorlick, 2013, Pediatric blood & cancer.

Initial testing of the hypoxia‐activated prodrug PR‐104 by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2011, Pediatric blood & cancer.

Evaluation of arsenic trioxide by the pediatric preclinical testing program with a focus on Ewing sarcoma

P. Houghton, J. Toretsky, Min H. Kang, 2012, Pediatric blood & cancer.

Probable fatal drug interaction between intravenous fenretinide, ceftriaxone, and acetaminophen: a case report from a New Approaches to Neuroblastoma (NANT) Phase I study

S. Groshen, K. Matthay, R. Sposto, 2014, BMC Research Notes.

Phase I trial of fenretinide lym-x-sorb oral powder in adults with solid tumors and lymphomas.

J. Doroshow, S. Kummar, A. Murgo, 2011, Anticancer research.

Initial testing (stage 1) of mapatumumab (HGS‐ETR1) by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2009, Pediatric blood & cancer.

Abstract LB-353: Pediatric Preclinical Testing Program (PPTP) stage 1 evaluation of cabozantinib.

S. Keir, J. Maris, P. Houghton, 2013 .

Abstract C206: Pediatric Preclinical Testing Program (PPTP) evaluation of BMN 673, an inhibitor of Poly-ADP Ribose Polymerase (PARP), alone and with Temozolomide (TMZ).

S. Keir, J. Maris, P. Houghton, 2013 .

Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2012, Pediatric blood & cancer.

Pharmacokinetics of 11-hydroxyaclacinomycin X (ID-6105), a novel anthracycline, after i.v. bolus multiple administration in rats

Young-Soo Hong, Jung Joon Lee, Sukgil Song, 2005, Archives of pharmacal research.

Inhibitory effects of tetrahydropapaverine on serotonin biosynthesis in murine mastocytoma P815 cells.

Myung-Koo Lee, Eung Il Kim, Min H. Kang, 2004, Life Science.

Reduction of serotonin content by tetrahydropapaveroline in murine mastocytoma P815 cells

J. Hong, Myung-Koo Lee, Eung Il Kim, 2003, Neuroscience Letters.

Identification of Mithramycin Analogues with Improved Targeting of the EWS-FLI1 Transcription Factor

L. Turner, S. Lessnick, L. Helman, 2016, Clinical Cancer Research.

Phase I trial of intravenous fenretinide (4-HPR) plus safingol in advanced malignancies

D. Gerber, S. Awasthi, Min H. Kang, 2023, Cancer Chemotherapy and Pharmacology.

Fenretinide (4-HPR)/Lym-X-Sorb (LXS) oral powder plus ketoconazole in patients with high-risk (HR) recurrent or resistant neuroblastoma: A New Approach to Neuroblastoma Therapy (NANT) Consortium trial.

S. Groshen, K. Matthay, Shengping Yang, 2014 .

Ceramide synthase-6 confers resistance to chemotherapy by binding to CD95/Fas in T-cell acute lymphoblastic leukemia

Shengping Yang, Sung-Jen Wei, Min H. Kang, 2018, Cell Death & Disease.

Assessing combinations of cytotoxic agents using leukemia cell lines.

C. Reynolds, Min H. Kang, B. Maurer, 2007, Current drug targets.

The P-glycoprotein antagonist PSC 833 increases the plasma concentrations of 6alpha-hydroxypaclitaxel, a major metabolite of paclitaxel.

T. Fojo, S. Bates, M. Blagosklonny, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Initial testing of aplidin by the pediatric pre‐clinical testing program

S. Keir, J. Maris, P. Houghton, 2009, Pediatric blood & cancer.

Abstract LB-049: Low plasma levels of 13-cis-retinoic acid (isotretinoin) and its active metabolite 4-oxo-13-cis-retinoic acid are associated with lower overall survival of high-risk neuroblastoma patients

A. Naranjo, Shengping Yang, J. Villablanca, 2017 .

Bcl-2 family of proteins as therapeutic targets in genitourinary neoplasms.

W. Figg, D. Price, Min H. Kang, 2013, Clinical genitourinary cancer.

Testing of the topoisomerase 1 inhibitor Genz‐644282 by the pediatric preclinical testing program

S. Keir, J. Maris, B. Teicher, 2012, Pediatric blood & cancer.

B- to plasma-cell terminal differentiation entails oxidative stress and profound reshaping of the antioxidant responses.

J. Fujii, S. Rhee, R. Sitia, 2010, Antioxidants & redox signaling.

Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2012, Pediatric blood & cancer.